AUA 2023: Dr. Stratton discusses prostate cancer research
Kelly L. Stratton, MD, FACS, recaps several presentations on prostate cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.
In this video, Kelly L. Stratton, MD, FACS, recaps several presentations from the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
The following research/presentations are discussed:
1. Panel Discussion: Triple Therapy vs. Chemotherapy/ADT for Newly Diagnosed mHSPC Patients (Treatment intensification)
2. MP29-01 (Saad et al): Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprviation therapy and docetaxel in ARASENS
3. LBA02-09 (Shore et al): EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer
4. Debate: Renaming Gleason 6 Prostate Cancer
5. Advanced Prostate Cancer: AUA/SUO Guideline (2023)
The management of high-risk localized prostate cancer: Back to the future
April 5th 2024"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.
BCG-unresponsive NMIBC: Advancements are finally moving the needle
February 1st 2024"I predict 2024 will be a banner year for progress in the management of [NMIBC], and not only will we be moving the needle but also turning up the volume in this historically quiet space," writes Michael S. Cookson, MD, MMHC, FACS.
Updates on advanced bladder cancer treatment
October 30th 2023"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.
